Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
Mazindol is an oral small-molecule sympathomimetic amine approved in 1980 for weight management and appetite suppression. It functions as a central nervous system stimulant with anorectic properties. The drug is indicated for short-term adjunctive therapy in weight reduction programs.
Declining commercial opportunity with minimal team expansion expected as product approaches loss of exclusivity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Worked on MAZANOR at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Mazindol offers limited career development opportunities given its LOE-approaching status and zero linked job postings. Roles available focus on defending market share and managing generic transition rather than growth initiatives.